Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, Boente CS, Crouch ER, Hubbard GB, Rogers DL, VanderVeen D, Yang MB, Cheung NL, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group.
Freedman SF, et al. Among authors: hubbard gb.
Ophthalmology. 2022 Oct;129(10):1120-1128. doi: 10.1016/j.ophtha.2022.05.019. Epub 2022 Jun 1.
Ophthalmology. 2022.
PMID: 35660415
Free PMC article.